SUMMARY The efficacy and safety of roxithromycin 300 mg once a day was compared with that of erythromycin 500 mg twice a day, both for seven days, in a double blind study of 281 patients (188 men, 93 women) with genitourinary chlamydial infections. At the end of the treatment 251 (89%) patients were evaluable, and at follow up two weeks later 227 (81%) were evaluable. The bacteriological cure rate was close to 100% at the end of both treatment regimens. At follow up 55/75 (73%) evaluable men and 38/39 (97%) evaluable women treated with roxithromycin were chlamydia negative compared with 50/71 (70%) evaluable men and 37/42 (88%) evaluable women treated with erythromycin. Of the 47 who were still chlamydia positive, reinfection could not be excluded in half the men and all the women.
Tetracycline and erythromycin are the drugs of choice in treating genitourinary chlamydial infections. The recommended periods of treatment and daily doses have varied in different studies from one to two weeks and from 1 g to 2 g divided into two, three, or even four daily doses.' Compliance of patients and thus the result of treatment depends, among other things, on the simplicity of the treatment. Roxithromycin is a new macrolide antibiotic with the same structure as erythromycin but a longer half life of about 10-12 hours, which indicates that this drug can be administered once a day. In vitro and in vivo studies have shown that roxithromycin is effective against Chlamydia trachomatis,23 and that it is safe, well tolerated, and well absorbed after administration by mouth.3 To evaluate this further, we compared treatment with roxithromycin 300 mg a day with erythromycin 500 mg twice a day, both for seven days, in men and women with uncomplicated genitourinary chlamydial infections.
Patients, materials, and methods All men and women attending our outpatient venereal disease clinic are screened routinely for genitourinary chlamydial infections. We asked all patients who attended with uncomplicated chlamydial infections during a four month period to participate in the study. We excluded patients who had received antibiotics within the previous three days, who had concomitant gonococcal infection, a history of hypersensitivity to macrolide antibiotics, or severely impaired hepatic or renal function, and pregnant and nursing women.
We randomly assigned the patients to a double blind, double dummy, multiple dose trial, comparing roxithromycin 300 mg once a day with erythromycin ethylsuccinate 500 mg twice a day by mouth for seven days.
We asked the patients to return on days 8 Roxithromycin v erythromycin against genitourinary chlamydial infections was 84% (57/68) in those treated with roxithromycin and 82% (50/61) in those treated with erythromycin (not significant). Those who still had symptoms were all chlamydia positive because of reinfection or relapse.
At the day 21 follow up visit the clinical efficacy rate in the 42 evaluable women who had had symptoms initially was 95% (20/21) in those treated with roxithromycin and 86% (18/21) in those treated with erythromycin (not significant). Those who still had symptoms were all chlamydia positive, and reinfection could not be excluded.
Side effects
The most common side effects were gastrointestinal complaints including abdominal pain and nausea, which were recorded in 15% (21/137) of the patients receiving roxithromycin and 16% (23/144) of those receiving erythromycin. Other minor side effects, such as tiredness, headache, and slight itching, were registered equally often in 1% to 5% of patients receiving either treatment regimen. Vaginal candidiasis was found in two women, one treated with roxithromycin and one with erythromycin. Slight erythema was seen in two patients treated with erythromycin. None ofthe recorded side effects necessitated discontinuation of the treatment.
Laboratory tests Two men, who had normal results before treatment and were both treated with erythromycin, showed increased liver function test results after treatment, one had a raised total bilirubin concentration only, and one had increased serum glutamic oxaloacetic transaminase (SGOT) and lactate dehydrogenase (LDH) activities. These patients had no known history of liver disease. None of the other patients tested showed any signs of haematological, renal, or hepatic toxicity during treatment.
Discussion
The recommended optimum daily doses and periods of treatment for eradicating genitourinary chlamydial infections differ between studies of patients treated with tetracycline or erythromycin. Treatments Erythromycin given in doses of 2 g a day has a high incidence of gastrointestinal side effects that decreases compliance and makes more patients discontinue the treatment.'4 There therefore seems to be a need for further studies elucidating the effect of other macrolides in genitourinary chlamydial infections. In this study we found that roxithromycin 300 mg once a day and erythromycin 500 mg twice a day, given orally for seven days, had similar effects. Gastrointestinal side effects were recorded in about 15% ofthe patients irrespective of the treatment, but not to a degree that caused any of the patients evaluable to discontinue the treatment. That less frequent administration of treatment is an important advantage in patient compliance has been shown in a study comparing treatment with doxycycline with tetracycline in patients with gonococcal infections.'5 Roxithromycin should therefore be preferable to erythromycin when treating patients with chlamydial infections. Some studies have found that more women than men with chlamydial infections are cured when given the same treatment," 4 a difference that might be related to lower serum concentrations in patients with greater body weights. 14 The same trend was also found in this study, with higher cure rates in women than men in both treatment groups. The cure rates in different studies are difficult to compare because of differences in duration of follow up and whether sexual partners are treated epidemiologically. In this study half the men and all the women still chlamydia positive when evaluated two weeks after the end of the treatment might have been reinfected, which gave a cure rate for roxithromycin of 74% to 87% in men and 97% to 100% in women. The corresponding cure rate for erythromycin was 71% to 87% in men and 88% to 100% in women. We therefore conclude that roxithromycin seems to be a safe and effective alternative treatment for genitourinary chlamydial infections, and has the advantage of being administered as a single daily dose.
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